CDXS
Codexis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CDXS
Codexis, Inc.
A leading enzyme engineering company enabling the promise of synthetic biology
200 Penobscot Drive
, Redwood City
, California 94063
--
Codexis, Inc., was founded in Delaware in January 2002. Its patented technology platform can create optimized biocatalysts that make existing industrial production processes faster, cleaner and more efficient, and can enable new industrial processes to have the potential for commercial scale. The company has commercialized its biocatalysts in the pharmaceutical industry and, after years of research and development cooperation with Shell, is starting to develop biocatalysts for the production of advanced biofuels. The company also leverages its technology platform to pursue solutions with biocatalyst capabilities in other bioindustrial markets, including carbon management, chemicals and water treatment.
Earnings Call
Q1/2025
Estimate EPS-0.21
Actual EPS-0.25
Estimate Revenue9.66M
Actual Revenue7.50M
Codexis Q1 2025: Key Contradictions in GMP Partnerships, Margin Strategies, and Pharma Pipeline
May 20,2025 06:06
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.15
Actual EPS-0.16
Estimate Revenue14.18M
Actual Revenue15.30M
Codexis Q2 2025: Navigating Contradictions in Revenue Growth, Lab Expansion, and Partnering Strategies
Aug 13,2025 08:06
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CDXS has released its 2025 Q3 earnings. EPS was reported at -0.22, versus the expected -0.13, missing expectations. The chart below visualizes how CDXS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CDXS has released its 2025 Q3 earnings report, with revenue of 8.60M, reflecting a YoY change of -32.98%, and net profit of -19.61M, showing a YoY change of 4.97%. The Sankey diagram below clearly presents CDXS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
